A Pilot Study Examining Selinexor’s Ability to Overcome Resistance in Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy
Sponsor: Karyopharm
Protocol Number: IST-321
Start Date: Not IRB approved yet
Not active
A Pilot Study Examining Selinexor’s Ability to Overcome Resistance in Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy
Sponsor: Karyopharm
Protocol Number: IST-321
Start Date: Not IRB approved yet
Not active